

Cara Therapeutics (CARA)

Initiation of Coverage

December 9, 2014

SUMMARY AND INVESTMENT THESIS

We are initiating coverage of Cara Therapeutics (CARA) with a BUY rating and \$20 price target. CARA is a clinical-stage biopharmaceutical company focused on developing and commercializing novel and proprietary chemical entities that selectively target kappa-opioid receptors involved with pain. The lead product candidate is intravenous CR845, which is an injectable version of a first-in-class kappa-opioid receptor-based peripheral analgesic designed to provide pain relief without stimulating mu-opioid receptors, which trigger many unwanted side effects. CARA has completed two phase II trials investigating IV CR845 in both soft- (laparoscopic hysterectomy) and hard-tissue (bunionectomy) surgeries, successfully demonstrating significant pain relief and a consistent ability to decrease opioid-related adverse events. Currently, CARA is expecting to begin phase III pivotal trials for IV CR845 in IHI5. CARA reported positive phase Ia/Ib data on the oral tablet formulation of CR845 just last week.

First-in-class kappa in acute pain: CR845 is a first-in-class novel pain therapeutic. As it is an opioid receptor, CR845 has, much like its mu-opioid receptor cousin, demonstrated effective acute pain relief in both of its phase IIb acute pain trials following soft- and hard-tissue surgeries. Due to its specific formulation, CR845 does not cross the blood/brain barrier and affect the central nervous system (CNS), thus negating the side effects that sidelined kappa-receptor agonists in the 1980s.

Opioid pain relief without the side effects: Though mu-opioids are considered the standard of care in acute pain, they have many unwanted side effects. As CR845 is a selective kappa-opioid receptor agonist, it does not activate the mu-receptors that generate the adverse reactions, such as respiratory depression, euphoria, nausea, and vomiting.

Low abuse potential could lead to unscheduled drug: One of the significant benefits of CR845 is that it does not produce the euphoria typical in mu-opioids. With this lack of euphoria, there is a decrease in potential abuse and addiction. In the company's human abuse liability study CR845 had a significantly ($p < 0.0001$) lower "liking" score compared to IV Talwin (pentazocine). CARA management believes they may be able to get CR845 as a schedule V drug or with no designation, which would make for a significant advantage over current therapies.

Large market opportunity with significant unmet need: The post-operative pain market is estimated to be ~\$6B in the US, with ~300 million IV units dosed per year. With the multi-modal analgesia as a standard of care and 75% of patients reporting adverse events from their pain medications, we believe CR845 has the ability to draw significant market share if approved.

CARA

Rating: BUY

Price Target: \$20.00

Market Data

Price:	\$9.85
52-week high:	\$23.25
52-week low:	\$7.53
Shares out:	22.78MM
Shares short:	486.70K
Average volume (10-day):	90,450

Valuation Metrics

Market cap:	224.36MM
Enterprise value:	169.17MM

Financial Highlights

Cash/equivalents:	\$58.39MM
Debt:	\$0.00

REV (\$MM)	2013	2014	2015E
Q1	0	0.178	0
Q2	9.973	0.960	0
Q3	1.018	1.125	0
Q4	0.973	0E	0
FY	11.964	2.263E	0

EPS (\$)	2013	2014	2015E
Q1	(0.48)	(0.22)	--
Q2	0.33	(0.16)	--
Q3	(1.07)	(0.28)	--
Q4	(0.49)	(0.39)E	--
FY	(0.74)	(1.06)E	(1.40)

One-Year History



Jim Molloy

Specialty Pharmaceuticals & Biotech
617-532-6421
jimm@ssrp.com

SUMMARY AND INVESTMENT THESIS

We are initiating coverage of Cara Therapeutics (CARA) with a BUY rating and \$20 price target. CARA is a clinical-stage biopharmaceutical company focused on developing and commercializing novel and proprietary chemical entities that selectively target kappa-opioid receptors involved with pain. The lead product candidate is intravenous CR845, which is an injectable version of a first-in-class kappa-opioid receptor-based peripheral analgesic designed to provide pain relief without stimulating mu-opioid receptors, which trigger many unwanted side effects. CARA has completed two phase II trials investigating IV CR845 in both soft- (laparoscopic hysterectomy) and hard-tissue (bunionectomy) surgeries, successfully demonstrating significant pain relief and a consistent ability to decrease opioid-related adverse events. Currently, CARA is expecting to begin phase III pivotal trials for IV CR845 in 1H15. CARA reported positive phase Ia/Ib data on the oral tablet formulation of CR845 just last week.

TOP REASONS TO OWN CARA

- 1. First-in-class kappa in acute pain:** CR845 is a first-in-class novel pain therapeutic. As it is an opioid receptor, CR845 has, much like its mu-opioid receptor cousin, demonstrated effective acute pain relief in both of its phase IIb acute pain trials following soft- and hard-tissue surgeries. Due to its specific formulation, CR845 does not cross the blood/brain barrier and affect the central nervous system (CNS), thus negating the side effects that sidelined kappa-receptor agonists in the 1980s.
- 2. Opioid pain relief without the side effects:** Though mu-opioids are considered the standard of care in acute pain, they have many unwanted side effects. As CR845 is a selective kappa-opioid receptor agonist, it does not activate the mu-receptors that generate the adverse reactions, such as respiratory depression, euphoria, nausea, and vomiting.
- 3. Low abuse potential could lead to unscheduled drug:** One of the significant benefits of CR845 is that it does not produce the euphoria typical in mu-opioids. With this lack of euphoria, there is a decrease in potential abuse and addiction. In the company's human abuse liability study CR845 had a significantly ($p < 0.0001$) lower "liking" score compared to IV Talwin (pentazocine). CARA management believes they may be able to get CR845 as a schedule V drug or with no designation, which would make for a significant advantage over current therapies.
- 4. Large market opportunity with significant unmet need:** The post-operative pain market is estimated to be ~\$6B in the US, with ~300 million IV units dosed per year. With the multi-modal analgesia as a standard of care and 75% of patients reporting adverse events from their pain medications, we believe CR845 has the ability to draw significant market share if approved.
- 5. Pruritus opportunity could ultimately dwarf pain indication:** The company is conducting a phase II trial in uremic pruritus, with PK data expected in December 2014 and topline results in 2Q15. Uremic pruritus (itching) is an unmet medical need that presents in 40-50% of adults with chronic kidney disease, while generalized pruritus affects up to 8% of the US adult population. Should CARA demonstrate positive phase II data in December 2014/2Q15 this could be a significant value driver for the shares.

Figure 1. Upcoming Potential Catalysts

Event	Expected Timing
End of phase 2 meeting with FDA for IV formulation	Dec-14
Phase 2 PK data CR845 for uremic pruritis	Dec-14
Start IV formulation phase 3 trials	1Q15
Start phase 2 proof of concept trial in oral version	1Q15
Phase 2 data CR845 for uremic pruritis	2Q15

Source: SSRP Estimates

VALUATION

We value CARA at \$20/share based on a sum-of-the-parts analysis, with IV CR845 valued at \$14/share based on a 3.5x multiple of 2019 sales of \$294MM discounted four years at 25%, oral CR845 valued at \$3/share based on a 3.5x multiple of 2020 sales of \$175MM discounted five years at 50%, and our remaining value based on cash (end 2015) and technology of \$3/share. We estimate a ~\$70MM raise in 2015.

Figure 2. Sum-of-the-Parts Analysis

Sum-of-the-parts value: BDSI		
Segment	Valuation (000's)	Per share value
CR845: IV post-op pain	\$426,778	\$14.0
CR845 - oral formulation	\$80,658	\$3.0
Cash (end '15) & tech value	\$92,909	\$3.0
SUM	\$600,345	\$20
Shares out '15E (000)		30,838

Source: SSRP Estimates


COMPANY DESCRIPTION

CARA is an emerging biotechnology company focused on developing novel therapeutics to treat pain and inflammation. Its lead product candidate is CR845, a best-in-class peripherally selective kappa-opioid receptor-based molecule for the treatment of acute and chronic pain as well as neuropathic and inflammatory pain.

CARA has completed two phase II trials in pain relief following soft- (laparoscopic hysterectomy) and hard-tissue (bunionectomy) surgical procedures. In the soft tissue trial, both the primary and secondary endpoints were met. In the hard tissue trial, topline data showed that the primary endpoint of reduction in pain over 24 hours was met, as was the secondary endpoint of reduction in pain intensity over the entire 48-hour dosing period. CARA is currently planning three phase III clinical trials with the FDA with an anticipated start of enrollment in 1H15.

CARA also has developed both a capsule and tablet oral formulation of CR845. The capsule formulation successfully completed a proof-of-concept phase I trial in April 2012 looking at bioavailability, safety, and efficacy. The tablet formulation just completed phase Ia/Ib trials last week, with a phase IIa proof-of-concept trial in acute pain expected to start during the first half of 2015.

Figure 3. Kappa-opioid Receptor



Source: Wu et al., Nature 485 (7398)327-32

CR845 — KAPPA-OPIOID RECEPTOR AGONIST

Kappa- vs. Mu-Opioid Receptors

Kappa-opioid receptors are one of the three classic opioid receptors primarily located on the neural synapse of the brain and pain neurons in the central nervous system (CNS). There are three classic opioid receptors: mu, delta, and kappa. These receptors are responsible for the release of dopamine, which is associated with stimulating the brain's reward and pleasure centers. The most commonly known of these receptors is the mu receptor, which is activated by opioids such as morphine and can cause pain relief, sedation, and euphoria. Though opioids are highly effective analgesics, they often have serious side effects such as nausea, vomiting, respiratory depression, and reduction in gastrointestinal motility. Due to their ability to cause a state of euphoria, drugs that stimulate mu-opioid receptors also tend to cause physical and physiological dependence that leads to addiction.

Lead product candidate CR845 is a peripherally acting kappa-opioid-receptor agonist for the treatment of both chronic and acute pain. It is designed to treat pain via activation of the peripheral kappa-opioid receptors without triggering mu-opioid receptors. By not triggering the mu-opioid receptors, CR845 bypasses the unwanted opioid-related side effects, such as nausea and vomiting and, more importantly, respiratory depression and potential addiction.

Not Your Typical Kappa

- *No interaction with the central nervous system:* Early on, neurobiologists considered the idea of kappa-opioid receptors as possible targets for pain. However, they soon discovered that due to the activation of kappa-opioid receptors in the CNS, several serious side effects were observed. These included acute psychiatric disorders, dysphoria, depression, and hallucinations. CR845, however, is unique. CR845 is designed with specific chemical characteristics that restrict it from entering the blood/brain barrier and CNS. Therefore, CR845 only acts on those nerve receptors outside of the brain and spinal cord. This peripheral action allows CR845 to be a powerful analgesic without the unwanted CNS side effects.
- *Reduction in standard mu-opioid-related side effects:* Morphine and the morphine derivatives OxyContin and Vicodin are the most commonly prescribed mu-opioids for both acute and chronic pain. These strong mu-opioid analgesics have been associated with post-operative opioid-induced respiratory depression (POIRD) and post-operative nausea and vomiting (PONV), as well as opioid-induced bowel dysfunction (OBD). As CR845 is a highly selective kappa receptor, it has shown statistically significant reduction of opioid-related adverse effects such as POIRD and PONV.
- *Abuse potential is limited with CR845:* Current mu-opioid treatments are known to cause feelings of euphoria, which has shown an increased potential for abuse and addiction. In fact, studies have shown a rapidly growing problem of abuse, with an 81% increase in abuse of prescription pain drugs (primarily from OxyContin and Vicodin) from 1992-2003¹. Activation of kappa receptors does not cause euphoria, which makes CR845 less likely to be abused. CR845 demonstrated positive abuse liability study data in October 2014 showing lower "likeability" vs. IV pentazocine ($p < 0.0001$). CARA management plans to ask the FDA that, if approved, CR845 be either schedule V or an unscheduled pain reliever. This would offer a significant competitive advantage over other scheduled drugs.
- *Safer drug-drug interaction profile:* Another benefit of CR845 is that it is a peptide composed of four non-natural D-amino acids that are not metabolized in the liver. This means it will not interact with liver enzymes that are responsible for the metabolism of some of the most commonly used drugs like statins, ACE inhibitors, and some beta-blockers.
- *IV to oral step down:* CARA is developing CR845 in at least two formulations — intravenous (IV) and tablet form. CARA intends to have the IV formulation in the acute or hospital setting to be used pre- and post-operatively. With the IV phase II trials indicating 24 hours of statistically significant pain relief after the post-operative pain therapies dissipate, CARA can perpetuate the use of CR845 by offering a tablet form. Once patients no longer need the IV formulation for pain, they can "step down" to the oral formulation upon discharge from the hospital. The tablet form also expands the marketplace for CR845, as it can be given for chronic pain.

¹ National Center on Addiction and Substance Abuse

Intravenous CR845 and Acute Pain

By definition, acute pain occurs suddenly, often as a result of illness, trauma or surgery. Though onset of acute pain is rapid and may resolve over the short term, it may also last for days or weeks depending on the severity of the injury or illness and how rapidly the patient recovers and heals.

Pain and surgery tend to go hand in hand, and postoperative pain is a substantial market of the overall pain marketplace. A recent study indicated that there are more than 46 million inpatient² and 53 million outpatient² surgeries performed in the US annually. According to the updated practice guidelines developed by the American Society of Anesthesiologists, the current standard for surgical pain management is a multimodal approach. This would consist of administration of two or more drugs that act on different pain mechanisms. Post-surgical pain is usually administered via IV and is usually a product containing mu-opioids such as oxycodone, oxymorphone, and hydrocodone. There are ~300 million intravenous anesthetic units dosed per year in the US.


Phase IIb Clinical Trials

Laparoscopic Hysterectomy (CLIN2002)

In June 2012 CARA completed a multicenter, double-randomized, double-blind, placebo-controlled phase IIb trial consisting of 203 patients at 22 sites in the US. Patients were administered either placebo or 0.04 mg/kg IV CR845 preoperatively and post-surgery; if they had a pain intensity score of ≥ 40 on a 100-point scale, they were randomized to receive either placebo or one dose of 0.04 mg/kg IV CR845. Efficacy was measured using time-specific 24-hour pain intensity difference. In summary, there were four measureable cohorts: placebo/placebo, CR845/placebo, placebo/CR845 and CR845/CR845.

The primary endpoint of reduction in total rescue morphine consumption in the first 24 hours post-surgery met statistical significance, with the CR845/CR845 group using approximately 33% less morphine than those in the placebo/placebo group.

Figure 4. Rescue Morphine Use




Source: Company Documents

For the secondary endpoint of efficacy compared to placebo in pain reduction up to 24 hours, the CR845/CR845 group exhibited a statistically significant reduction of pain over a 24-hour time period as indicated by an improvement in 0-24 hour mean summed pain intensity difference (SPID). Pain intensity difference (PID) in the CR845/CR845 group also exhibited statistically significant improvements in pain over 0-4, 0-8, and 0-16 hour time intervals.


² International Association for the Study of Pain

Figure 5. Phase IIb SPID from 0-24 Hours



Source: Company Documents


Figure 6. Phase IIb PID at Specific Time Intervals



Source: Company Documents

With the reduced use of rescue morphine, there was also a reduction in opioid-related side effects such as nausea, vomiting, and pruritus. Also important to note, there were no CNS-related effects seen with centrally acting kappa opioid agonists.

Figure 7. Incidence of Opioid-Related AEs



Source: Company Documents

*p≤0.001 **p≤0.05

Figure 8. Phase IIb Laparoscopic Hysterectomy Trial

CLIN2002 - Phase 2b Laparoscopic Hysterectomy Trial	
Aim	Determine if CR845 is effective in treating pain associated with laparoscopic hysterectomy
Design	Multi-center, double-randomized, double-blind, placebo controlled - one preemptive IV dose and one postoperative IV dose, rescue morphine allowed
Dosing	CR845 0.04 mg/kg single IV dose administered pre-op and post-op for pain compared to IV placebo ¹ : 1) IV CR845 both pre- and post-op (CR845/CR845) 2) Placebo pre-op and IV CR845 post-op (Placebo/CR845) 3) IV CR845 pre-op and Placebo post-op (CR845/Placebo) 4) Placebo pre-op and Placebo post-op (Placebo/Placebo)
Endpoints	1': Total morphine consumption in the first 24 hours in patients who are re-randomized in post-op period - 24 hours 2': To evaluate the efficacy of CR845 compared to placebo for reducing pain following laparoscopic hysterectomy - up to 24 hours 2': To evaluate the effect of CR845 compared to placebo on the use of opioid analgesics during post-op period - UP to 24 hours
Patients	N = 203
Safety	Nausea 26.1% CR845 vs. 51.2% placebo, Vomiting 1.7% CR845 vs. 8.3% placebo, also decreased pruritus
Results - 6/11/12	Patients given pre & post op CR845 resulted in stat. signif. reduction (~33%) in rescue morphine use over 24 hrs post-surgery. Patient group exhibited ~ 2X or (~100%) increase in their calculated 24-hr PID (p=0.002) and SPID (p=0.003) value compared to placebo. Signif 24-hr analgesic seen in single post-op dose of CR845 where SPID value (p=0.014) increased by more than 50% when compared to placebo.


Source: Company Documents

Bunionectomy (CLIN2003)

In October 2013 CARA completed a randomized, double-blind, placebo-controlled trial consisting of 51 patients in the US. Patients received an initial bolus dose of CR845 or placebo at randomization and again at patient's request, 30-60 minutes later and thereafter as needed up to every eight hours over a 48-hour dosing period. Fentanyl was available as a "rescue" medication for patients not reporting adequate pain relief.


In the completer analysis, the CR845 treatment arm met the primary endpoint of statistically significant ($p < 0.05$) reduction in pain intensity as measured by the SPID score over the initial 24-hour period compared to placebo. The CR845 arm also met the secondary endpoint of a statistical ($p < 0.025$) reduction in pain intensity over the entire 48-hour dosing period.

Figure 9. SPID 0-24 Hours, 0-36 Hours, 0-48 Hours in Completer Population



Source: Company Documents

* $p \leq 0.05$ ** $p \leq 0.03$

Figure 10. SPID 0-24 Hours, 0-36 Hours, 0-48 Hours in mITT Population (Completers + Non-Completers)

Source: Company Documents

In addition, the CR845 treatment resulted in a statistically significant reduction in the incidence of opioid-related adverse events of nausea and vomiting (by 60% and 80%, respectively; $p < 0.05$) compared to placebo during the 48-hour period of treatment. Though there was no observed difference in the overall mean fentanyl use between the placebo and CR845 treatment groups, CARA believes the ability of CR845 to reduce nausea and vomiting despite fentanyl use is due to a direct anti-vomiting or anti-nausea effect resulting from its kappa-opioid-agonist mechanism of action.

Figure 11. Phase II Bunionectomy Trial

CLIN2003 - Phase 2 Bunionectomy Trial	
Aim	Determine the analgesic efficacy as well as safety and tolerability of CR845 after a bunionectomy
Design	Single-center, randomized, double-blind, placebo controlled parallel group proof of concept study
Dosing	CR845 0.04mg/kg initial dose followed by prn dosing
Endpoints	1': 24 hour summed pain intensity differences (SPID24) 2': Evaluate the efficacy of CR845 compared to placebo in reducing pain following bunionectomy (up to 48 hours) 2': Evaluate the effect of CR845 compared to placebo on the use of rescue opioids (fentanyl) during the post-op period (up to 48 hours)
Patients	N = 51
Safety	Safe & well tolerated, stat. signif reduction in incidence of opioid-related AE of nausea and vomiting (by 60% and 80%)
Results - 10/29/2013	Primary endpoint met: stat. signif. reduction in pain intensity as measured by SPID over initial 24 hours v. placebo ($p < 0.05$). Secondary endpoint met: stat. signif. reduction in pain intensity over entire 48-hour dosing period $p < 0.025$. CR845 also resulted in a stat. signif. reduction in the incidence of opioid-related adverse events of nausea (by 60%) and vomiting (by 80%) at $p < 0.05$ compared to placebo over the 48 hours of treatment.

Phase 3 Clinical Development Plan for IV CR845

With the success of the phase IIb trials in both hard- and soft-tissue surgeries, CARA is currently planning its phase III clinical program for management of acute pain in a hospital setting. Current assumptions are that CARA will be required to complete two phase III trials, one with pain resulting from a soft-tissue surgery and one in patients with pain resulting from a hard-tissue surgery.

- *Potential phase III trial (CLIN3001)*: CLIN3001 is a randomized, double-blind, placebo-controlled trial with ~600 female patients with postoperative pain after laparoscopic hysterectomy. Patients will be assigned one of three doses or placebo. The primary endpoint is expected to be the SPID at 24 hours with secondary endpoints of rescue morphine use, SPID at other time points, and occurrence of nausea and vomiting.
- *Potential phase III trial (CLIN3002)*: CLIN3002 is a randomized, double-blind, placebo controlled trial with ~600 male or female patients with postoperative pain after bunionectomy. Patients will be assigned one of three doses or placebo. The primary endpoint is expected to be the SPID at 48 hours with secondary endpoints of rescue morphine use, SPID at other time points, and occurrence of nausea and vomiting.
- *Potential phase III trial (CLIN3003)*: CLIN3003 is a supportive trial in ~450 patients with postoperative pain following either laparoscopic hysterectomy or bunionectomy surgery. This trial is looking at efficacy of IV CR845 when dosed pre- and post-surgery as compared with IV CR845 only post-surgery. This will be a three-arm trial — CR845 pre- and post-surgery, post-surgery only, or just placebo. Primary endpoints are expected to be at either SPID at 24 or 48 hours with secondary endpoints of rescue morphine use, SPID at other time points, TOPAR at 24 and 48 hours, and occurrence of nausea and vomiting.

Oral CR845 and Chronic Pain


Chronic pain can be progressive, arising from conditions such as systemic inflammation and musculoskeletal problems, the most common of which is lower back pain. Chronic pain is defined as any pain that lasts longer than three to six months. Co-morbidities associated with chronic pain include cancer, rheumatoid arthritis, and fibromyalgia or nerve damage from diabetes. Treatments for chronic pain are dependent on severity.

Current non-opioids: Generally, mild to moderate pain is treated with over-the-counter products such as aspirin, acetaminophen, and naproxen sodium. Non-opioid therapies can be limiting due to their limited efficacy and side effects such as liver toxicity, bleeding, serious GI complications (including ulcers and kidney damage), and even more serious cardiovascular thrombotic events such as stroke and heart attack.


Opioids: Opioids are the most commonly prescribed drug for both acute and chronic pain, with mu-opioids at the front of the pack. Morphine and the morphine derivatives OxyContin and Vicodin are all commonly used. Though powerful in their pain relief, opioids have safety and tolerability issues³. Chronic opioid users can develop a tolerance for the opioid, which results in the need for a higher dose. Also, due to their CNS activity, mu-opioids can produce feelings of euphoria that can lead to abuse and addiction.

Yet even with these risks, opioids remain the most prescribed pain medication with ~40% of the \$20.6B global pain market in 2011. According to IMS Health, in 2012 the US market for opioid painkillers reached \$9.4B.

³ Johnson, et al. Journal of Pain and Symptom Management, March 2005

Figure 12. 2011 Total Market Sales — \$20.6B

Source: Decision Rsrcs, Chronic Pain Study, Nov. 2011

Figure 13. Annual US Prescriptions of Opioid Painkillers

Source: IMS Health

Phase Ia Clinical Trial

In April 2012 CARA completed a first-in-man phase I clinical trial of an oral formulation of CR845. The trial was a single-center, double-blind, placebo-controlled study to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics of CR845 in 50 healthy patients. Patients were randomized and received either placebo or one of four single ascending doses of the capsule of CR845. The study demonstrated a mean oral bioavailability of 16% across all groups, under fast with peak and total exposures proportional to each dose.

Phase Ib Clinical Development Plan for Oral CR845

CARA conducted both a single ascending- and multiple ascending-dose trial in the first half of 2014, which read out positive data just last week. The company plans to initiate a phase IIa proof-of-concept trial in acute pain in the first half of 2015.

- The single ascending-dose study:** This study included six tablet strengths from 0.1 mg to 10 mg and demonstrated a mean oral bioavailability of 10% across all dose groups under fasting conditions, with a range of maximum plasma concentrations of CR845 bracketing the concentrations seen in previously successful phase II trials with IV CR845. All tested dose strengths were also shown to be active at the kappa opioid receptor, as assessed by statistically significant ($p < 0.0001$) acute changes in blood measurements of an established neuroendocrine biomarker.
- The multiple ascending-dose study:** This study used repeat-doses of the 0.1 mg, 1 mg, and 5 mg tablets administered twice a day for one week. All tablet doses were well tolerated with no serious adverse events (SAEs) reported and all adverse events (AEs) were mild and generally similar to those reported with IV CR845. Clinical safety laboratory measurements were normal across all tablet strengths after single or repeat dosing.

Potential “Blockbuster” Opportunity in Uremic Pruritus as Well

In August 2014 CARA initiated a proof-of-concept phase II trial for IV CR845 for the treatment of uremic pruritus (UP), a systemic condition with high prevalence in dialysis patients for which there are no approved therapeutics in the US. We anticipate topline dose-ranging pharmacokinetic (PK) and safety data from this trial in December 2014, with topline efficacy results anticipated in 2Q15.

According to the Journal of the European Academy of Dermatology and Venereology, UP is present in 40-50% of adults with chronic kidney disease (CKD), demonstrating that UP remains an important clinical symptom and health issue in the estimated 20 million US patients with CKD (Centers for Disease Control).

In some patients UP occurs intermittently and lasts only several minutes, but other patients suffer from prolonged periods of severe pruritus, which can occur throughout the day and night. The occurrence, duration, and intensity of UP can change over time and the itching is usually worst at night. The areas most commonly affected by UP are the back, limbs, chest, and head, but 20-50% of patients experience generalized pruritus. External heat, sweat, and stress can aggravate UP, and cold or hot showers can alleviate symptoms.

UP has a substantial effect on quality of life, as it causes serious discomfort, anxiety, depression, and sleeping disorders. Sleeping disorders cause chronic fatigue, are associated with disturbance of day and night rhythm, and have a negative influence on mental and physical capacity. UP is increasingly recognized as an indicator of excess mortality risk in patients with CKD.

While there are no approved therapeutics in the US for CKD, this systemic condition is found to be highly prevalent amongst dialysis patients. Measures to control UP in patients on dialysis include optimization of dialysis efficacy, use of biocompatible dialysis membranes, and improvement of the nutritional status of the patient. Adequate control of plasma levels of calcium and phosphorus and the concomitant treatment of secondary hyperparathyroidism can ameliorate pruritus symptoms in some cases. In patients with CKD, cases of pruritus caused by liver diseases (e.g. hepatitis), primary skin diseases (e.g. atopic dermatitis, contact dermatitis, psoriasis, and urticaria), and endocrine disorders (e.g. Graves disease, hypothyroidism, and diabetes mellitus) require specific treatments. Available treatment options for UP include both topical and systemic therapies.

MANAGEMENT

Derek Chalmers, PhD, CEO, President and Director: Dr. Chalmers has 17 years' experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Dr. Chalmers served as a principal investigator at Neurocrine Biosciences (NBIX-\$18.97-NR) prior to co-founding Arena Pharmaceuticals (ARNA-\$4.13-NR) in 1997. He served as vice president and executive director of ARNA until May 2004, prior to co-founding CARA. Dr. Chalmers has extensive corporate financing experience, having led both private and IPO roadshow teams. Dr. Chalmers is an inventor or co-inventor on more than 50 issued or pending US patents.

Michael Lewis, PhD, Chief Scientific Officer: Dr. Lewis has had extensive experience in the biopharmaceutical industry, and prior to that, about five years of experience in opioid research at the National Institutes of Health and the University of Michigan. After establishing and directing a molecular pharmacology lab at DuPont, Dr. Lewis co-founded Cephalon, Inc., serving as director of pharmacology and senior director of scientific affairs. He participated in pre- and post-IPO road shows in Japan and the US as well as presentations to obtain corporate partners, including Schering-Plough and Kyowa Hakko. Dr. Lewis later co-founded and served as chief scientific advisor to Adolor Corporation and also participated on the company's analgesics development team and assisted in pre-IPO financing and corporate partnering presentations. Dr. Lewis was subsequently invited by Dr. Chalmers to co-found ARNA, and he served as a pre-IPO director and chief scientific advisor to ARNA. Dr. Lewis is presently a director of PolyMedix, Inc., a privately held biotechnology company that is developing antimicrobial agents based on a novel computational chemistry platform. Dr. Lewis is an inventor or co-inventor on 15 issued US patents and is an author or co-author of more than 40 publications on opioids, including journal articles, invited reviews, and book chapters.

Josef Schoell, Chief Financial Officer: Mr. Schoell has more than 20 years of financial and accounting experience, including 10 years in the biotechnology industry. From 2003 until joining the company, Mr. Schoell was a consultant with Robert Half Management Resources. From 1995 to 2002 he served as the chief financial officer and vice president-finance of the American Biogenetic Sciences Inc. and controller from 1992 to 1995. From 1988 until joining American Biogenetic Sciences Inc., Mr. Schoell was an independent consultant providing financial accounting and computer services. From 1978 until 1988, Mr. Schoell served in various financial and accounting positions with JP Stevens. Mr. Schoell is a graduate of New York University Stern School of Business, is a certified public accountant in New York State and a member of the New York State Society of Certified Public Accountants, American Institute of Certified Public Accountants, and Financial Executives International.

Joseph Stauffer, Chief Medical Officer: Dr. Stauffer brings to CARA more than 15 years of pain development and regulatory experience, having served as chief medical officer at numerous specialty pharmaceutical companies, including Ikaria, Inc. and Alpharma. While at Alpharma, prior to the company's acquisition by King Pharmaceuticals, he led the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the FDA. Prior to getting his industry start as the global medical director for pain therapeutics at Abbott Laboratories (ABT-\$45.71-NR), Dr. Stauffer served as a medical review officer in the FDA's Anti-inflammatory and Analgesic Division of the Center for Drug Evaluation and Research, where he reviewed regulatory filings for a variety of pain and anti-inflammatory compounds. Dr. Stauffer has also been a founding member of several FDA, industry, and academic working groups, including the Analgesic Clinical Trial Translations, Innovations, Opportunities and Networks (ACTION) and the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMPACT).

Figure 14. Potential Clinical Trial Timelines




Figure 15. Quarterly Income Statement

CARA Therapeutics										
Quarterly income statement										
(\$000 except per share)	2013A				2013A Year	2014E				2014E Year
	1QA	2QA	3QA	4QA		1QA	2QA	3QA	4QE	
Revenues										
CR845 - IV version										
CR845 - oral version										
License & milestones		\$9,637			\$9,637		\$302			\$302
Collaborative revenues		336	\$1,018	\$973	2,327	\$178	658	\$1,125		1,961
Total Revenue	\$0	\$9,973	\$1,018	\$973	\$11,964	\$178	\$960	\$1,125	\$0	\$2,263
Expenses:										
Cost of Revenue (COGS)	-	-	-	-	-	-	-	-	-	-
Gross Margin	-	9,973	1,018	973	11,964	178	960	1,125	-	2,263
Research and development	922	2,021	3,764	1,978	8,685	2,201	3,200	6,208	7,250	18,859
General and administrative	588	1,033	795	1,100	3,516	1,398	1,472	1,250	1,250	5,370
Total operating expenses	1,510	3,054	4,559	3,078	12,201	3,599	4,672	7,458	8,500	24,229
Income (loss) from Operations	(1,510)	6,919	(3,541)	(2,105)	(237)	(3,421)	(3,712)	(6,333)	(8,500)	(21,966)
Interest income (expense), net	(1,129)	(1,602)	(1,034)	9	(3,756)	22	56	26	(500)	(396)
Other (exp) gain, net										
Income (loss) before taxes	(2,639)	5,317	(4,575)	(2,096)	(3,993)	(3,399)	(3,656)	(6,307)	(9,000)	(22,362)
Income tax exp (benefit)	(7)	(20)	(9)	(3)	(3)	(16)	(11)	(32)		
Net income (Loss)	(2,632)	5,337	(4,566)	(2,093)	(3,990)	(3,383)	(3,645)	(6,275)	(9,000)	(22,303)
Net income to common	(1,741)	5,337	(4,566)	(2,093)	(3,072)					
Earning per Share (EPS)	(\$0.48)	\$0.33	(\$1.07)	(\$0.49)	(\$0.74)	(\$0.22)	(\$0.16)	(\$0.28)	(\$0.39)	(\$1.06)
Adj EPS ex-1x & non-cash items										
Weighted avg. shares (000)	3,659	4,288	4,288	4,288	4,133	15,654	22,608	22,713	22,963	20,985
Fully diluted shares (000)	15,998	15,972	17,352	19,467	17,197	16,551	23,686	23,677	24,463	22,094

Source: Company reports and SSRP estimates

Specialty Pharmaceuticals
Jim Molloy (617) 532-6421 jimm@jssrp.com

Figure 16. Annual Income Statement

CARA Therapeutics							
Annual income statement							
(\$000 except per share)	2013A	2014E	2015E	2016E	2017E	2018E	Comments
Revenues							
CR845 - IV version					\$35,699	\$164,141	Launch 2Q17
CR845 - oral version						-	2019 launch
License & milestones	\$9,637	\$302	-	-	-	-	
Collaborative revenues	2,327	1,961	-	-	-	-	
Total Revenue	\$11,964	\$2,263	\$0	\$0	\$35,699	\$164,141	
Expenses:							
Cost of Revenue (COGS)	-	-	-	-	5,355	19,697	
Gross Margin	11,964	2,263	-	-	30,345	144,444	
R&D	8,685	18,859	31,250	25,250	27,750	30,000	
G&A	3,516	5,370	6,000	8,000	30,000	36,000	
Total op exp	12,201	24,229	37,250	33,250	57,750	66,000	
Inc/(loss) from Ops	(237)	(21,966)	(37,250)	(33,250)	(27,405)	78,444	
Int income (exp), net	(3,756)	(396)	(2,000)	(2,000)	(2,000)	(1,999)	
Other expenses, net	-	-	-	-	-	-	
Inc/(loss) before taxes	(3,993)	(22,362)	(39,250)	(35,250)	(29,405)	76,445	
Income tax exp (benefit)	(3)	-	-	-	-	-	
Net income (Loss)	(\$3,990)	(\$22,303)	(\$39,250)	(\$35,250)	(\$29,405)	\$76,445	
Net income to common	(\$3,072)						
Earning per Share	(\$0.74)	(\$1.06)	(\$1.40)	(\$1.20)	(\$0.95)	\$2.05	
Weighted avg. shares (000)	4,133	20,985	28,088	29,338	30,838	32,339	
Fully diluted shares (000)	17,197	22,094	30,838	32,338	34,338	37,339	

Source: Company reports and SSRP estimates

Specialty Pharmaceuticals
Jim Molloy (617) 532-6421 jimm@jssrp.com

Figure 17. Balance Sheet

CARA Therapeutics Balance sheet									
(\$000's except per share)	2013A	1Q14A	2Q14A	3Q14A	2014E	2015E	2016E	2017E	2018E
ASSETS:									
Current assets									
Cash and cash equivalents	12,357	67,038	62,812	58,393	51,614	82,909	50,399	26,485	123,747
Income tax receivable	61	46	57	89	70	70	70	70	70
Prepaid expenses and other	2,140	1,142	2,186	928	500	500	750	750	750
Total current assets	14,558	68,226	65,055	59,410	52,184	83,479	51,219	27,305	124,567
PP&E	2,825	2,629	2,439	2,262	3,100	3,500	3,750	4,250	4,750
Restricted cash	700	700	700	700	700	700	700	700	700
Total Assets	18,083	71,555	68,194	62,372	55,984	87,679	55,669	32,255	130,017
LIABILITIES									
Total current liabilities	5,433	5,753	5,617	6,093	6,250	7,000	7,500	10,000	30,000
Total liabilities	6,572	6,827	6,626	7,037	7,389	8,139	8,639	11,139	31,139
Shareholders Equity									
Convertible preferred share	65,586								
Beneficial conversion feature									
Common stock	4	23	23	23	22	22	22	22	22
Additional paid-in-capital	8,377	130,544	131,029	131,341	133,332	203,527	206,267	209,758	211,075
Accumulated deficit	(62,456)	(65,839)	(69,484)	(76,029)	(84,759)	(124,009)	(159,259)	(188,664)	(112,219)
Total shareholders' equity	11,511	64,728	61,568	55,335	48,595	79,540	47,030	21,116	98,878
Total liabilities & net worth	18,083	71,555	68,194	62,372	55,984	87,679	55,669	32,255	130,017

Figure 18. Statement of Cash Flow

CARA Therapeutics Statement of cash flows									
(\$000's except per share)	2013E	1Q14A	2Q14A	3Q14A	2014E	2015E	2016E	2017E	2018E
Operating Activities									
Net Income (Loss)	(\$3,963)	(\$3,383)	(\$7,028)	(\$13,573)	(\$22,303)	(\$39,250)	(\$35,250)	(\$29,405)	\$76,445
Adjustments:									
Dep and Amort	789	197	393	590	800	1,000	1,250	1,500	1,750
Non-cash comp expense	123	353	809	1,031	1,250	1,500	1,500	1,750	2,000
Change license agreement liab	(35)				(35)	(35)	(35)	(35)	(35)
Accrued interest & amort. notes	3,605					-	-	-	-
Changes in assets and liabilities	2,431	(193)	(1,374)	328	1,868	350	(125)	2,125	17,000
Net cash from operations	2,829	(3,091)	(7,330)	(11,818)	(18,620)	(36,635)	(32,860)	(24,265)	96,960
Investing Activities									
Purchase of equipment	(5)	-	(6)	(27)	(35)	(100)	(150)	(150)	(200)
Net cash from investing	(5)	-	(6)	(27)	(35)	(100)	(150)	(150)	(200)
Financing Activities									
Proceeds convert notes	1,462								
Financing costs convert notes	(70)								
Repayment of LTD	(618)								
Issuance of common stock		57,772	57,762	57,762	57,762	67,680	-		
Stock option exercise			29	119	150	350	500	501	502
Proceeds Jr. converts	7,642								
Net cash from financing	8,416	57,772	57,791	57,881	57,912	68,030	500	501	502
Net change in cash	11,240	54,681	50,455	46,036	39,257	31,295	(32,510)	(23,914)	97,262
Cash at beginning of year	1,117	12,357	12,357	12,357	12,357	51,614	82,909	50,399	26,485
Cash at end of period	12,357	67,038	62,812	58,393	51,614	82,909	50,399	26,485	123,747

RISKS TO PRICE TARGET ESTIMATE

Exogenous events could impact our outlook. We believe pharmaceutical companies have the least control over competitive, political, and regulatory risks. Although we have incorporated competitive assumptions into our forecasts, there may be other risks beyond the scope of our analysis. Changes in the drug reimbursement system, as well as any political or regulatory amendments, may significantly influence the earnings power of these companies.

Actual clinical results and the FDA's conclusions may deviate from expectations. Many of our assumptions are based on a review of incomplete clinical trial data available in the public domain. Often our conclusions are drawn from early stage data, which may not be reflected by pivotal studies. Furthermore, the FDA's conclusions may not coincide with our own, materially changing our revenue and earnings assumptions.

Compliance issues, product recalls, and other mandates by regulatory authorities could materially change our expectations. Regulatory compliance issues, ranging from accounting irregularities to defective manufacturing practices, could materially change our assumptions and earnings outlook. Unanticipated product recalls and labeling changes could also have adverse consequences on our earnings assumptions.

Legal risks could lead to additional liabilities and revenue loss. In addition to the expenses incurred by patent challenges, product liability and other legal suits could occur and lead to additional liabilities and revenue loss, which could substantially change our financial assumptions.

Important Disclosures and Disclaimers — Fourth Quarter 2014

Analyst Certification: Each research analyst who authored the attached research report certifies the following: 1) All of the views expressed in this research report reflect my personal opinions about the subject company or any company mentioned in this research report; 2) I have not and will not receive compensation in exchange for the recommendation or views in this research report; and 3) Neither I nor the firm that employs me believes or have reason to believe that I have any material conflicts of interest with regard to the subject company or any company mentioned in this research report at the time of its publication.

Analyst/Firm Financial Interest/Control: Neither the analyst nor any members of his/her household has a financial interest in the covered company, or companies mentioned in this research report, including the ownership of shares, warrants, or options on the subject company's securities. In addition, neither the analyst nor any member of his/her family is an officer, director or advisory board member of the subject company. At the end of the month immediately preceding the publication of this research report, the firm and/or its affiliates did not beneficially own 1% or more of any class of common equity securities of the subject company, nor any company mentioned in this research report. Summer Street Research Partners ("SSRP" or "the Company") does not make markets in any securities, including those of the subject companies in this research report. The research analysts' compensation is not directly related to the specific recommendations or views expressed in this research report. Research Analyst(s) compensation is however based upon various factors including SSRP's total revenues, a portion of which may in the future be generated by investment-banking related activities.

Investment Banking and Other Services: SSRP has not provided investment-banking, advisory or other similar services to the subject companies described in this research report, nor are they clients of the SSRP. Further, the firm and its affiliates have not managed or co-managed a public/private offering of securities for the subject companies in this research report, and have not received compensation for investment-banking services from the subject companies in this research report. We expect to receive or intend to seek compensation from the subject companies for investment-banking related services in three months from the date of this research report. The firm has not received investment-banking revenues or participated in a public/private offering of securities as a manager or co-manager of the subject company's securities in the past 12 month from the date of this research report. Nor has the firm or its research analysts received compensation from the subject company or any company mentioned in this research report for products and services in the past 12 months. No research analyst, employee, or affiliate of SSRP with the ability to influence the substance of this research report has received any compensation for products and service provided to the subject company in the past 12 months.

Definition of SSRP's Stock Rating System as used in this Research Report: BUY – We believe the stock's total return will significantly outperform its peer group; NEUTRAL – We believe the stock's total return will not be significantly different than its peer group; SELL – We believe the stock's total return will significantly under perform its peer group.

General Disclaimers: The information contained herein is intended for distribution to institutional investors and is for informational purposes only. SSRP's research reports should be considered as only a single factor in making an investment decision. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness and it should not be relied upon as such. Additional information is available by contacting SSRP. Neither the information nor any opinion expressed constitutes an offer, or an invitation to make an offer to buy or sell any securities. The data contained herein is intended for the sole and exclusive use of clients of SSRP. No reproduction, transmission or replication of any of the information or data contained within this document may be done without the expressed written consent of SSRP. Medical Consulting Research Inc. (MCRI) is a division of SSRP.

Investment Rating Distribution for the Period 7/1/14 through 9/30/14:

Rating	Count	Percentage	Investment Banking Services (12 months)
BUY	25	89%	16%
NEUTRAL	3	11%	0%
SELL	0	0%	0%
Companies under coverage at 9/30/14	28	100%	14%

We have assigned an investment rating for at least one year for the following subject companies mentioned in this report:

CARA

Ratings History

Date	Rating	Share Price	Price Target
12/9/14	BUY	\$9.85	\$20.00

CARA Investment Risks

- Exogenous events could impact our outlook. Pharmaceutical companies have the least control over competitive, political, and regulatory risks.
- Actual clinical results and the FDA's conclusions may deviate from expectations.
- Compliance issues, product recalls, and other mandates by regulatory authorities could materially change our expectations.
- Legal risks could lead to additional liabilities and revenue loss.

Valuation Method for Price Target: Sum of the parts

